ML Innovations

ML Bio Solutions, a subsidiary of BridgeBio Pharma, is a clinical-stage biotechnology company dedicated to developing therapies for rare genetic diseases, specifically limb-girdle muscular dystrophy type 2I (LGMD2I). The company's lead program, BBP-418, is an investigational oral substrate replacement therapy designed to address the underlying cause of LGMD2I by restoring the glycosylation of alpha-dystroglycan. Currently in Phase 3 clinical development, BBP-418 aims to stabilize or improve muscle function in patients who otherwise face progressive muscle weakness. ML Bio Solutions operates within BridgeBio's hub-and-spoke model, leveraging centralized resources to accelerate the development of targeted treatments for Mendelian diseases. The company was formerly known as ML Innovations before rebranding to reflect its focus on biological solutions for muscular dystrophies.